$PRQR News

ProQR to Participate in Upcoming Investor Conferences in September 2026

B of A Securities Initiates Coverage On ProQR Therapeutics with Buy Rating, Announces Price Target of $8

ProQR Announces Second Quarter 2026 Operating and Financial Results

ProQR Therapeutics Q2 EPS $(0.09) Beats $(0.14) Estimate, Sales $10.183M Beat $5.560M Estimate

ProQR Form4 Filing Shows CEO Daniel De Boer Buys 200,000 Shares At An Average Price Of $1.77; Increasing Direct Holdings to 500,000 Shares

ProQR Therapeutics Files Prospectus For Offering 3.03M Ordinary Shares On Behalf Of Selling Shareholder

ProQR Therapeutics: Human NTCP Data Strengthens The Axiomer Thesis

Evercore ISI Group Maintains Outperform on ProQR Therapeutics, Raises Price Target to $6

Chardan Capital Maintains Buy on ProQR Therapeutics, Lowers Price Target to $3

ProQR Announces Positive Phase 1 Target Engagement Data for AX-0810, Establishing First Clinical Validation of the Axiomer RNA Editing Platform

ProQR Therapeutics Announces Data From Its Ongoing Phase 1 Clinical Study Of AX-0810 Investigational Axiomer RNA Editing Oligonucleotide; Sees Target Engagement On All Key Biomarkers

ProQR Therapeutics N.V. (PRQR) Presents at 29th ASGCT Annual Meeting 2026 - Slideshow

ProQR Therapeutics N.V. (PRQR) Presents at TIDES USA 2026 - Slideshow

ProQR Therapeutics N.V. (NASDAQ:PRQR) Analysts Just Slashed This Year's Revenue Estimates By 22%

ProQR Announces First Quarter 2026 Operating and Financial Results

ProQR Therapeutics Q1 EPS $(0.15), Inline, Sales $2.381M Miss $5.530M Estimate

ProQR Announces Multiple Upcoming Scientific Conference Presentations Highlighting the Breadth of its Axiomer™ RNA Editing Platform

ProQR Announces Annual General Meeting of Shareholders to be Held June 2, 2026

ProQR Announces Nomination of Dr. Lykke Hinsch Gylvin to its Board of Directors

ProQR Therapeutics: Waiting On Proof As AX-0810 Data Approaches